Fleury Isabelle, MacDonald David, Shafey Mona, Christofides Anna, Sehn Laurie H
Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, University of Montreal, Montreal, QC H3T 1J4, Canada.
Division of Hematology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Curr Oncol. 2025 Feb 28;32(3):142. doi: 10.3390/curroncol32030142.
CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist. Bispecific antibodies (BsAbs), including glofitamab and epcoritamab, have demonstrated promising efficacy and represent a new treatment option in patients who are unsuitable for or have relapsed following CAR-T therapy. Bispecific antibodies have a manageable safety profile and are generally more widely accessible than CAR-T cell therapy. Case discussions in this paper illustrate the potential real-world application of BsAbs, highlighting their role in treating patients who have relapsed after or are unable to undergo CAR-T cell therapy. Overall, glofitamab and epcoritamab represent valuable treatment options in the evolving landscape of R/R DLBCL.
嵌合抗原受体T细胞（CAR-T）疗法显著改善了复发或难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL）患者的治疗结局，但资源有限、生产周期以及明显的毒性等挑战依然存在。双特异性抗体（BsAbs），包括戈利木单抗和依泊妥单抗，已显示出有前景的疗效，并为不适合接受CAR-T治疗或CAR-T治疗后复发的患者提供了一种新的治疗选择。双特异性抗体具有可控的安全性，并且通常比CAR-T细胞疗法更容易获得。本文中的病例讨论阐述了双特异性抗体在现实世界中的潜在应用，突出了它们在治疗CAR-T细胞治疗后复发或无法接受CAR-T细胞治疗的患者中的作用。总体而言，在R/R DLBCL不断变化的格局中，戈利木单抗和依泊妥单抗是有价值的治疗选择。
